Treatment for Chronic (Recurrent) C. difficile in Pediatric Patients
For pediatric patients with recurrent Clostridioides difficile infection, oral vancomycin using a tapered and pulsed regimen is the preferred treatment approach, with fecal microbiota transplantation reserved for multiple recurrences after antibiotic failure. 1
Treatment Algorithm Based on Number of Recurrences
First Recurrence (Non-severe)
For the first recurrence in children, you have two equally acceptable options 1:
- Oral metronidazole 7.5 mg/kg/dose TID or QID (max 500 mg/dose) for 10 days, OR
- Oral vancomycin 10 mg/kg/dose QID (max 125 mg/dose) for 10 days
Important caveat: If metronidazole was used for the initial episode, switch to vancomycin for the first recurrence rather than repeating metronidazole 1.
Second or Subsequent Recurrences
This is where treatment strategy fundamentally changes. For children with ≥2 recurrences, the IDSA/SHEA guidelines recommend 1:
Primary option: Vancomycin tapered and pulsed regimen
- 10 mg/kg QID (max 125 mg) for 10-14 days
- Then 10 mg/kg BID (max 125 mg) for 1 week
- Then 10 mg/kg daily (max 125 mg) for 1 week
- Then 10 mg/kg every 2-3 days (max 125 mg) for 2-8 weeks
Alternative options:
- Vancomycin 10 mg/kg QID for 10 days followed by rifaximin for 20 days (weak recommendation; note that rifaximin lacks FDA approval and established pediatric dosing for children <12 years) 1
- Fidaxomicin (emerging evidence supports this—see below)
- Fecal microbiota transplantation after failing appropriate antibiotic treatments
Emerging Evidence: Fidaxomicin in Pediatric Recurrent CDI
While the 2018 IDSA/SHEA guidelines note fidaxomicin was not FDA-approved for children <18 years at that time 1, more recent real-world data strongly support its use. A 2025 multicenter retrospective study of 95 pediatric patients (88% treated for recurrent CDI) showed 2:
- 83.1% clinical cure or improvement by day 14
- Only 21.5% recurrence rate at day 60 among initial responders
- Well-tolerated with minimal adverse events (abdominal pain, nausea)
- Particularly valuable given that 86% of patients had medical/surgical comorbidities
Clinical pearl: Patients with inflammatory bowel disease were less likely to achieve initial clinical cure (OR 0.27), but those who did respond had no increased recurrence risk 2.
Fecal Microbiota Transplantation (FMT)
FMT should be considered after at least 2 recurrences (meaning 3 total CDI episodes) have been treated with appropriate antibiotics 1. The guidelines provide a strong recommendation with moderate quality evidence for FMT in multiple recurrences 1.
For pediatric patients specifically, FMT carries a weak recommendation with very low quality evidence, but this reflects limited pediatric-specific data rather than safety concerns 1. Recent case reports demonstrate FMT can be lifesaving even in fulminant pediatric CDI when surgery is contraindicated 3.
Critical Distinctions from Adult Treatment
The pediatric guidelines differ from adult recommendations in important ways:
Metronidazole remains acceptable for first recurrence in children (unlike adults where vancomycin is strongly preferred) 1
Fidaxomicin data are emerging: While not included in 2018 guidelines for routine pediatric use, 2025 data suggest it's effective and well-tolerated 2, 4, 5
IBD patients require special consideration: They have lower initial cure rates but similar recurrence rates once they respond 2
Common Pitfalls to Avoid
- Don't repeat metronidazole for recurrent CDI if it was used initially—switch to vancomycin 1
- Don't use standard 10-day vancomycin courses for second/subsequent recurrences—the tapered/pulsed regimen is specifically designed to prevent further recurrence 1
- Don't delay FMT indefinitely in multiply recurrent cases—it has strong evidence and should be offered after 2-3 failed antibiotic courses 1
- Be cautious with rifaximin in young children—it lacks FDA approval and pediatric dosing for those <12 years 1
Strength of Evidence Considerations
The pediatric CDI treatment recommendations carry predominantly weak recommendations with low-quality evidence because randomized controlled trials in children are lacking 1. However, the adult literature showing vancomycin superiority over metronidazole, combined with emerging pediatric real-world data on fidaxomicin 2, 6, supports an evolving treatment paradigm favoring vancomycin-based regimens and newer agents for recurrent disease.
The strongest recommendation in the guidelines (strong/moderate evidence) is for FMT in multiple recurrences 1, making it the most evidence-based intervention when antibiotics fail.